Clinical trial
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
NCT00318656 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00318656 |
|---|---|
| Title | 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes |
| Official title | Comparison of the Effects of Rosiglitazone and Glimepiride, Both Given in Combination With Metformin, on 24-Hour Glycemia in Type 2 Diabetes Patients Not Controlled With Metformin Alone. A 3-Month Multicentre, Randomized, Parallel-Group, Open-Label Study. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Non-Insulin-Dependent Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | rosiglitazone-metformin fixed dose combination, metformin + glimepiride |
| Enrollment | 23 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Apr 27, 2006 |
| Last update posted | May 7, 2009 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: